News & Updates

Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in combination with multiple daily insulin injections (MDII) is associated with an improvement in A1c and a reduction in insulin doses without increased hypoglycaemia, reports a study.

Treatment with efgartigimod, a neonatal Fc receptor (FcRn) antagonist, in patients with chronic or persistent immune thrombocytopenia (ITP) resulted in a higher proportion of patients achieving a sustained platelet count response compared with placebo, according to the ADVANCE IV* trial presented at ASH 2022.

Treatment with finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist with a short half-life, results in decreased 24-h, daytime, and night-time systolic blood pressure (SBP), results of a study have shown.

A recent study reports an overall risk of 8.6 percent for hydroxychloroquine (HCQ) retinopathy after 15 years in a large cohort with active surveillance retinopathy screening. Notably, most of these cases are mild, and a higher HCQ dose appears to result in progressively greater risk for incident retinopathy.

Treatment with rituximab in patients with pemphigus appears to yield long-term cardiovascular and metabolic protection as compared with conventional immunosuppressants, a study has shown.